Catalent Pharma Solutions will acquire Aptuit's Clinical Trial Supplies business for $410 million in a cash and debt free basis. The acquisition is intended to substantially expand Catalent’s Development & Clinical Services business, transforming it into the second largest global provider of clinical supply solutions. After the transaction, Aptuit will focus on its integrated discovery to mid-phase development business.
“This transaction builds important expertise, scale and capability for our Development & Clinical Services business to better meet our customers’ needs globally,” said John Chiminski, president and chief executive officer of Catalent. “This transaction also strengthens Catalent’s global leadership in development solutions and advanced delivery technologies for drugs and biologics.”
Catalent’s Development & Clinical Services business offers clinical supply services, analytical chemistry, respiratory product development, regulatory consulting, and biologics cell line development. Catalent has made several recent investments to extend the capabilities and capacity of the business.
Aptuit will retain discovery, development and manufacturing facilities in the U.S., Europe and Asia. Aptuit offers integrated early development capabilities, including discovery, early development, solid state chemistry, sterile fill parenterals, high potency APIs through Class V and formulation development.
“This agreement puts Aptuit in a better position to focus on the scientific excellence that our customers want,” said Timothy C. Tyson, Aptuit's chairman and chief executive officer. “Focusing on our expertise in discovery and development services leverages our leadership position, and allows us to concentrate on delivering high-growth, high-value scientific services from discovery to mid-phase development.”
The transaction is expected to close by the end of the year, pending regulatory approval.